Details of the Drug

General Information of Drug (ID: DMXOHYH)

Drug Name

Etavopivat

Synonyms

Etavopivat; FT-4202; Etavopivat [INN]; Etavopivat [USAN]; 2245053-57-8; V4E0A9M44Q; 1-Propanone, 1-(5-((2,3-dihydro-1,4-dioxino(2,3-b)pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)-3-hydroxy-2-phenyl-, (2S)-; 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)-; Etavopivat [USAN:INN]; UNII-V4E0A9M44Q; CHEMBL4650332; SCHEMBL20511240; GTPL11975; GLXC-25164; EX-A6335; FT4202; WHO 11646; AKOS040757470; MS-28351; CS-0213556; (2S)-1-(5-(2,3-Dihydro(1,4)dioxino(2,3-b)pyridine-7- sulfonyl)-3,4,5,6-tetrahydropyrrolo(3,4-C)pyrrol-2(1H)- YL)-3-hydroxy-2-phenylpropan-1-one; (2S)-1-[5-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylsulfonyl)-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrol-2-yl]-3-hydroxy-2-phenylpropan-1-one; (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2/3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C22H23N3O6S
Canonical SMILES: C1COC2=C(O1)C=C(C=N2)S(=O)(=O)N3CC4=C(C3)CN(C4)C(=O)C(CO)C5=CC=CC=C5
InChI: InChI=1S/C22H23N3O6S/c26-14-19(15-4-2-1-3-5-15)22(27)24-10-16-12-25(13-17(16)11-24)32(28,29)18-8-20-21(23-9-18)31-7-6-30-20/h1-5,8-9,19,26H,6-7,10-14H2/t19-/m1/s1
InChIKey: KZFFYEPYCVDOGE-LJQANCHMSA-N

Cross-matching ID

PubChem CID: 135338378
TTD ID: D5U4MY

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pyruvate kinase (PK)	TTABNSJ	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04624659) An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS). U.S.National Institutes of Health.
2	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219.